drugset / Trial / NCT01764854
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenapanor | Small molecule | 5 mg | — |
| Subject | Tenapanor | Small molecule | 45 mg | — |
| Subject | Tenapanor | Small molecule | 60 mg | — |